This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2015 Jul;29(7):1602-4.

doi: 10.1038/leu.2015.14. Epub 2015 Jan 30.

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

V Goede¹, K Fischer¹, A Engelke¹, R Schlag², S Lepretre³, L F C Montero⁴, M Montillo⁵, C Fegan⁶, E Asikanius⁷, K Humphrey⁸, G Fingerle-Rowson⁷, M Hallek⁹

Affiliations

Affiliations

¹ German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
² Oncology Practice, Würzburg, Germany.
³ Department of Hematology, Centre Henri Becquerel, Rouen, France.
⁴ Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.
⁵ Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.
⁶ Department of Hematology, University Hospital of Wales, Cardiff, UK.
⁷ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁸ F. Hoffmann-La Roche Ltd, Welwyn, UK.
⁹ 1] German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany [2] Cluster of Excellence 'Cellular Stress Responses in Aging Associated Diseases' (CECAD), University of Cologne, Cologne, Germany.

PMID: 25634683
DOI: 10.1038/leu.2015.14

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study

V Goede et al. Leukemia. 2015 Jul.

. 2015 Jul;29(7):1602-4.

doi: 10.1038/leu.2015.14. Epub 2015 Jan 30.

Authors

V Goede¹, K Fischer¹, A Engelke¹, R Schlag², S Lepretre³, L F C Montero⁴, M Montillo⁵, C Fegan⁶, E Asikanius⁷, K Humphrey⁸, G Fingerle-Rowson⁷, M Hallek⁹

Affiliations

¹ German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany.
² Oncology Practice, Würzburg, Germany.
³ Department of Hematology, Centre Henri Becquerel, Rouen, France.
⁴ Department of Hematology, Hospital Virgen de la Salud, Toledo, Spain.
⁵ Department of Hematology and Oncology, Ospedale Niguarda Ca' Granda, Milan, Italy.
⁶ Department of Hematology, University Hospital of Wales, Cardiff, UK.
⁷ F. Hoffmann-La Roche Ltd, Basel, Switzerland.
⁸ F. Hoffmann-La Roche Ltd, Welwyn, UK.
⁹ 1] German CLL Study Group (GCLLSG), Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University of Cologne, Cologne, Germany [2] Cluster of Excellence 'Cellular Stress Responses in Aging Associated Diseases' (CECAD), University of Cologne, Cologne, Germany.

PMID: 25634683
DOI: 10.1038/leu.2015.14

No abstract available

PubMed Disclaimer

References

1. Lancet Oncol. 2014 Sep;15(10):1090-9 - PubMed
1. Br J Haematol. 2011 Feb;152(3):295-306 - PubMed
1. Blood. 2008 Aug 15;112(4):975-80 - PubMed
1. Mol Cancer Ther. 2013 Oct;12 (10 ):2031-42 - PubMed
1. Blood. 2008 Jun 15;111(12):5446-56 - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.